Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.

Authors
  • Pakosch, Daria1
  • Papadimas, Dimitrios
  • Munding, Johanna
  • Kawa, Darafsch
  • Kriwalsky, Marcus Stephan
  • 1 Ruhr-University Bochum, Bochum, Germany. , (Germany)
Type
Published Article
Journal
Oral and maxillofacial surgery
Publication Date
Dec 01, 2013
Volume
17
Issue
4
Pages
303–306
Identifiers
DOI: 10.1007/s10006-012-0379-9
PMID: 23242941
Source
Medline
License
Unknown

Abstract

The anti-angiogenic agent, bevacizumab, may increase the risk of osteonecrosis of the jaw. This agent inhibits VEGF and, therefore, also presumably represses the vascularisation of the jaw, which leads to healing complications. Due to increasing use of bevacizumab, patients receiving this agent should be closely monitored for possible side effects.

Report this publication

Statistics

Seen <100 times